POLQ and renal cell carcinoma: Finally, POLθ (DNA polymerase-theta) inhibitors (e.g., novobiocin) are in first-in-human studies for DDR-altered cancers and could be biologically attractive for HRD-like RCC subsets, but no results in RCC are available [99] (Table 2).